uniQure stock: H.C. Wainwright cuts target to USD 65
Published on 11/19/2026 at 13:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst trims target amid uncertainty
- H.C. Wainwright retained its Buy rating on uniQure.
- The analyst linked the target reduction to uncertainty around four-year therapy data.
H.C. Wainwright cut its price target for uniQure from USD 80 to USD 65 on Wednesday, November 18, 2026, while keeping a Buy rating. Markets Insider reported that the firm cited increased uncertainty after four-year data for ifezuntirgene inilparvovec.
Four-year data shapes analyst view
H.C. Wainwright said it remained confident that the totality of evidence supported accelerated approval. The target reduction nevertheless signals a more cautious valuation view as the analyst weighs the therapy data.
uniQure stock traded at 18.90 euros on Lang & Schwarz at 13:04 CET on Thursday, November 19, 2026.
uniQure company details
- Company: uniQure
- ISIN: NL0010696654
- Market quote: EUR 18.90 on Lang & Schwarz at 13:04 CET on November 19, 2026
- Analyst action: H.C. Wainwright target USD 65 from USD 80; Buy rating maintained on November 18, 2026
The broader Dutch market is tracked through the AEX.
Disclaimer...
en | NL0010696654 | QURE | boerse | 70535712 | bgmi
